Preclinical evaluation of monoclonal antibody 14C5 for targeting pancreatic cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 2, 2010, Pages 193-205

  Vervoort, Liesbet ^a   Burvenich, Ingrid ^b   Staelens, Steven ^a   Dumolyn, Caroline ^a   Waegemans, Els ^a   Van Steenkiste, Magali ^a   Baird, Sarah K ^b   Scott, Andrew M ^b   De Vos, Filip ^a  

^a GHENT UNIVERSITY   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

111 indium; 131 iodine; Monoclonal antibody; Pancreatic cancer; Radioimmunodetection

Indexed keywords

4 BENZYLISOTHIOCYANATE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; 4 ISOTHIOCYANATOBENZYL DIETHYLENETRIAMINEPENTAACETIC ACID IN 111; ALPHAVBETA5 INTEGRIN; INDIUM 111; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14C5; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PANCREAS BIOPSY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIMMUNOASSAY; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; PANCREAS; PANCREATIC NEOPLASMS; PENTETIC ACID; RADIOIMMUNOASSAY; RADIOPHARMACEUTICALS; RECEPTORS, VITRONECTIN; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951946777     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0696     Document Type: Article

References (63)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581.
2. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004;363:1049.
3. 213Bi-CHX. A"-C595. Cancer Biol Ther 2005;4:848.
4. Sabbah E, Kadouche J, Ellison D, et al. In vitro and in vivo comparison of DTPA-and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer. Nucl Med Biol 2007;34:293.
5. Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006;12:4925.
6. Kigure S. Immunohistochemical study of the association between the progression of pancreatic ductal lesions and the expression of MUC1, MUC2, MUC5AC, and E-cadherin. Rinsho Byori 2006;54:447.
7. Gold DV, Cardillo T, Goldenberg DM, et al. Localization of pancreatic cancer with radiolabelled monoclonal antibody PAM4. Crit Rev Oncol Hematol 2001;39:147.
8. Cruz-Monserrate Z, O'Connor KL. Integrin alpha 6 beta 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation. Neoplasia 2008;10:408.
9. Longo R, Cacciamani F, Naso G, et al. Pancreatic cancer: From molecular signature to target therapy. Crit Rev Oncol Hematol 2008;68:197.
10. Burvenich I, Schoonooghe S, Blanckaert P, et al. Biodistribution and planar gamma camera imaging of (123) I-and (131) I-labelled F (ab') (2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Nucl Med Biol 2007;34:257.
11. De Potter CR, Schelfhout AM, De Smet FH, et al. A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasion. Am J Pathol 1994;144:95.
12. Coene E, Schelfhout AM, De Ridder L, et al. Generation of a monoclonal antibody directed against a human cell substrate adhesion molecule and the expression of the antigen in human tissues. Hybridoma 1997;16:77.
13. Burvenich I, Schoonooghe S, Cornelissen B, et al. In vitro and in vivo targeting properties of iodine-123-or iodine-131-labelled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model. Clin Cancer Res 2005;11:7288.
14. 123I-mAb 14C5: A new mAb for radioimmunodetection of tumor growth and metastasis in vivo. J Nucl Med 2004;45:1065.
15. 5. Mol Cancer Ther 2008;7:3771.
16. Grzesiak JJ, Ho JC, Moossa AR, et al. The integrin-extracellular matrix axis in pancreatic cancer. Pancreas 2007;35:293.
17. Mahadevan D, Von Hoff D. Tumor-stroma interactions in pancreatic ductal carcinoma. Mol Cancer Ther 2007;6:1186.
18. Masamune A, Kikuta K, Watanabe T, et al. Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut 2009;58:550.
19. Omary MB, Lugea A, Lowe AW, et al. The pancreatic stellate cell: A star on the rise in pancreatic diseases. J Clin Invest 2007;117:50.
20. Jaster R. Molecular regulation of pancreatic stellate cell function. Mol Cancer 2004;3:26.
21. 5to promote tumor cell dissemination in vivo. J Clin Invest 1997;99:1390.
22. Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005;128:907.
23. Rosendahl A, Neumann K, Chaloupka B, et al. Expression and distribution of VLA receptors in the pancreas: An immunohistochemical study. Pancreas 1993;8:711.
24. Gleason B, Adley B, Sambasiva R, et al. Immunohistochemical detection of the ß4 integrin subunit in pancreatic adenocarcinoma. J Histochem Cytochem 2005;53:799.
25. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labelled receptor targeted proteins. J Nucl Med 1993;34:1728.
26. Smith-Jones PM, Pandit-Taskar N, Cao W, et al. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 2008;35:343.
27. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumour cells in vitro: A comparison of nine radiolabels. J Nucl Med 1994;35:899.
28. Kyriakos RJ, Shih LB, Ong GL, et al. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992;52:835.
29. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123.
30. Verel I, Visser GWM, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005;46:164S.
31. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 1990;87:7235.
32. Liu A, Panousis C, Smyth FE, et al. Generation of antiidiotype antibodies for application in clinical immunotherapy laboratory analysis. Hybrid Hybridomics 2003;22:219.
33. Perk LR, Visser GW, Vosjan MJ, et al. (89) Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiomet al.s (90) Y and (177) Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46:1898.
34. Meares C, McCall M, Reardan D, et al. Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of met al. ions. Anal Biochem 1984;142:68.
35. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabelled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77.
36. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392.
37. Scott AM, Wiseman G, Welt S, et al. A phase I doseescalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639.
38. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200.
39. Koppe MJ, Postema EJ, Aarts F, et al. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 2005;24:539.
40. Dübbel S. Handbook of Therapeutic Antibodies. Volume I: Technologies. Darmstadt: Wiley-VCH, 2007.
41. Vaughan TJ, Williams AJ , Pritchard K, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14:309.
42. Gold DV, Goldenberg DM, Karacay H, et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 2008;68:4819.
43. Worlock AJ, Zalutsky MR, Metzgar RS. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. Cancer Res 1990;50:7246.
44. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006;281:951.
45. Clarke K, Lee FF, Brechbiel MW, et al. In vivo biodistribution of humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 2000;60:4804.
46. Sharkey RM, Motta-Henessy C, Pawlyk D, et al. Biodistribution and radiation dose estimates for yttrium-and iodine-labelled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumour xenografts. Cancer Res 1990;50:2330.
47. Michel BR, Ochakovskaya R, Mattes MJ. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: Importance of using residualizing radiolabels. Clin Cancer Res 2002;8:2632.
48. Behr TM, Béhé M, Stabin MG, et al. High-linear energy transfer (LET) a versus low-LET b emitters in radioimmunotherapy of solid tumors: Therapeutic efficacy and dose-limiting toxicity of 213Bi-versus 90Y-labelled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res 1999;59:2635.
49. 111In: An intrapatient comparison. Clin Cancer Res 2003;9 (suppl) : 3953S.
50. 186Re. J Nucl Med 2004;45:327.
51. DeNardo SJ, Motta-Henessy C, Pawlyk D, et al. Pharmacokinetics of chimeric L6 conjugated to indium-111-and yttrium-90-DOTA-peptide in tumour-bearing mice. J Nucl Med 1995;36:829.
52. 111In-DTPA-trastuzumab. Br J Pharmacol 2004;143:99.
53. 177Lu-DOTA-labelled a glycosylated monoclonal anti-L1-CAM antibody chCE7: Influence of the number of chelators on the in vitro and in vivo properties. Nucl Med Biol 2006;33:883.
54. Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005;11:7454.
55. 90Y radioimmunotherapy. J Nucl Med 2008;49:1066.
56. 90Y-labeled anti-LewisY monoclonal antibody B3. Clin Cancer Res 2000;6:1720.
57. Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. Pancreas 2008;9:251.
58. 90Yttrium- DOTA-labelled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer 2004;109:618.
59. Tolmachev V, Wållberg H, Andersson K, et al. The influence of Bz-DOTA and CHX-A"-DTPA on the biodistribution of ABD-fused anti-HER2 affibody molecules: Implications for (114m) In-mediated targeting therapy. Eur J Nucl Med Mol Imaging 2009;36:1460.
60. Wong JYC. Basic immunology of antibody targeted radiotherapy. Int J Radiat Oncol 2006;66: S8.
61. Sultana A, Shore S, Raraty MGT, et al. Randomised phase I/II trial assessing the safety and efficacy of radiolabelled anticarcinoembryonic antigen I131 KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 2009;9:66.
62. 111In in human myeloid leukemia cells. J Nucl Med 2006;47:827.
63. Constantini D, Chen P, Cai Z, et al. (111) In-labelled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS) : An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007;48:1357.